CERC-301

CERC-301
Names
	IUPAC name 4-Methylbenzyl (3S,4R)-3-fluoro-4-[(2-pyrimidinylamino)methyl]-1-piperidinecarboxylate
Identifiers
ChemSpider	9569140
Jmol 3D model	Interactive image
PubChem	11394238
UNII	5HAM167S5T
	InChI InChI=1S/C19H23FN4O2/c1-14-3-5-15(6-4-14)13-26-19(25)24-10-7-16(17(20)12-24)11-23-18-21-8-2-9-22-18/h2-6,8-9,16-17H,7,10-13H2,1H3,(H,21,22,23)/t16-,17-/m1/s1 Key: RECBFDWSXWAXHY-IAGOWNOFSA-N ; InChI=1/C19H23FN4O2/c1-14-3-5-15(6-4-14)13-26-19(25)24-10-7-16(17(20)12-24)11-23-18-21-8-2-9-22-18/h2-6,8-9,16-17H,7,10-13H2,1H3,(H,21,22,23)/t16-,17-/m1/s1 Key: RECBFDWSXWAXHY-IAGOWNOFBJ ;
	SMILES CC1=CC=C(C=C1)COC(=O)N2CC[C@@H]([C@@H](C2)F)CNC3=NC=CC=N3 ;
Properties
Chemical formula	C19H23FN4O2
Molar mass	358.42 g·mol−1
Vapor pressure	{{{value}}}
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

CERC-301 (formerly known as MK-0657) is an orally-active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD).^[1] In November 2013, phase II clinical trials were initiated,^[2] and in the same month, CERC-301 received Fast Track Designation from the Food and Drug Administration for TRD.^[3]

A pilot study was published in 2012,^[1] and a phase 2 trial was completed in 2014.^[4]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.